Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Prospect Capital Corporation — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Prospect Capital Corporation trades at $1.75 (market cap $974.22M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 12.9× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Prospect Capital Corporation for 78 Days on average.
| HALO | PSEC | |
|---|---|---|
Market Cap | $12.58B | $974.22M |
Volume | 2,179,278 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $115.22 | $3.05 |
52-Week Low | $61.63 | $1.82 |
Typical Hold Time | 1 Days | 78 Days |
Enterprise Value | $14.49B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PSEC trades at $1.72, down 6.52% today, amid bearish technical signals and mixed fundamentals. The stock shows consistent earnings beats but faces revenue volatility with negative 2025 results. Recent news highlights dividend distributions and portfolio management activity, while analysts remain cautious with 55% hold ratings. Technical indicators show oversold conditions with RSI below 10, but moving averages signal continued downward pressure.
PSEC presents a high-risk opportunity with an 18%+ yield and deep NAV discount, but faces significant headwinds from portfolio contraction and declining investment income. The dividend cut to $0.035 improves coverage, yet persistent NAV erosion and bearish analyst sentiment suggest limited near-term upside. Investors should weigh the attractive yield against fundamental deterioration and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
